Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With Multi-Dose CD30 CAR T Cells (RELY-30)
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs CART 30 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms RELY-30
- 13 Jun 2017 Status changed from not yet recruiting to recruiting.
- 11 Apr 2017 Planned number of patients changed from 14 to 18.
- 11 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.